Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8585646 | 0.85 | TLR8 (0.81) | TLR8MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL20434306 | 0.82 | TLR8 (1.00) | TLR8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10102121 | 0.82 | TLR8 (0.47) | TLR8MEN1KMT2ACYP2D6MAPT | |
| SCHEMBL2849398 | 0.80 | TLR8 (0.90) | TLR8MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL29442374 | 0.79 | TLR8 (0.78) | TLR8MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL18072294 | 0.79 | TLR8 (0.58) | TLR8MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL26345520 | 0.79 | TLR8 (0.78) | TLR8MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL12230238 | 0.79 | MAPT (0.45) | TLR8KMT2AGAAMAPTSMN1; SMN2 | |
| SCHEMBL5791298 | 0.79 | TLR8 (0.88) | TLR8MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL6742818 | 0.78 | TLR8 (0.45) | TLR8MEN1KMT2ACYP2D6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| EP-3784666-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2142543-B1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2008127678-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007044813-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | TLR8 4617/4885MEN1 2702/4885KMT2A 4376/4885 |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | TLR8 4849/4885MEN1 3593/4885KMT2A 2707/4885 |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | TLR8 4719/4885MEN1 1423/4885KMT2A 2819/4885 |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | TLR8 3886/4885MEN1 991/4885KMT2A 1824/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | TLR8 4719/4885MEN1 1423/4885KMT2A 2819/4885 |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | TLR8 4719/4885MEN1 1423/4885KMT2A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.